On the occasion of its quarterly publication, healthcare group AbbVie announces that it has raised its adjusted EPS guidance range for the full year 2024 from $10.97-11.17 to $11.13-11.33.

It reports adjusted EPS of $2.31 for the first quarter 2024, down 6.1% year-on-year, despite sales of over $12.3 billion, up 0.7% on a reported basis.

On an operational basis - i.e., excluding currency effects - revenues rose by 1.6%, with growth in oncology (+9.8%) and neuroscience (+16%) more than offsetting declines in its other portfolios.

Copyright (c) 2024 CercleFinance.com. All rights reserved.